Get the Stockscreener App
30.17
1.73%
-0.53
After Hours:
30.44
0.27
+0.89%
Alkermes Plc stock is traded at $30.17, with a volume of 2.45M.
It is down -1.73% in the last 24 hours and down -2.87% over the past month.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
See More
Previous Close:
$30.70
Open:
$30.34
24h Volume:
2.45M
Relative Volume:
1.24
Market Cap:
$4.98B
Revenue:
$1.51B
Net Income/Loss:
$333.35M
P/E Ratio:
15.47
EPS:
1.95
Net Cash Flow:
$315.22M
1W Performance:
+1.51%
1M Performance:
-2.87%
6M Performance:
-5.07%
1Y Performance:
+13.98%
1-Day Range:
$29.70
$30.69
1-Week Range:
$28.41
$32.13
52-Week Range:
$25.16
$36.45
Alkermes Plc Stock (ALKS) Company Profile
Name
Alkermes Plc
Sector
Phone
00-353-1-772-8000
Address
CONNAUGHT HOUSE, DUBLIN 4
Compare ALKS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
30.17 | 5.07B | 1.51B | 333.35M | 315.22M | 1.95 |
|
ZTS
Zoetis Inc
|
144.35 | 63.86B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.42 | 42.46B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.38 | 41.28B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.52 | 23.49B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
438.66 | 19.18B | 3.08B | 1.24B | 1.07B | 25.61 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-26-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Sep-03-25 | Initiated | Wells Fargo | Overweight |
| Jul-15-25 | Initiated | Goldman | Buy |
| Jun-17-25 | Upgrade | UBS | Neutral → Buy |
| May-28-25 | Initiated | Needham | Buy |
| Mar-13-25 | Initiated | RBC Capital Mkts | Sector Perform |
| Mar-04-25 | Upgrade | UBS | Sell → Neutral |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Nov-05-24 | Upgrade | Stifel | Hold → Buy |
| Jun-17-24 | Initiated | TD Cowen | Buy |
| Mar-19-24 | Initiated | Robert W. Baird | Outperform |
| Feb-20-24 | Downgrade | UBS | Neutral → Sell |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Oct-24-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-17-23 | Initiated | UBS | Neutral |
| Nov-03-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-14-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-16-22 | Initiated | Piper Sandler | Neutral |
| Apr-22-22 | Resumed | Goldman | Buy |
| Apr-20-22 | Initiated | Goldman | Buy |
| Jan-27-22 | Upgrade | Cantor Fitzgerald | Hold → Overweight |
| Dec-01-21 | Initiated | Citigroup | Neutral |
| Oct-07-21 | Upgrade | Jefferies | Hold → Buy |
| Sep-02-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Oct-15-20 | Upgrade | Mizuho | Neutral → Buy |
| Jul-30-20 | Downgrade | Goldman | Neutral → Sell |
| Feb-14-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Feb-14-20 | Reiterated | H.C. Wainwright | Neutral |
| Feb-14-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Jan-31-20 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Sep-05-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jul-15-19 | Upgrade | Goldman | Sell → Neutral |
| May-31-19 | Initiated | H.C. Wainwright | Neutral |
| May-01-19 | Downgrade | Citigroup | Buy → Neutral |
| Dec-19-18 | Downgrade | Goldman | Neutral → Sell |
| Dec-14-18 | Initiated | Wolfe Research | Underperform |
| Dec-13-18 | Downgrade | Credit Suisse | Outperform → Underperform |
| Nov-05-18 | Initiated | Piper Jaffray | Neutral |
| Aug-07-18 | Initiated | Stifel | Hold |
| Jun-21-18 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jun-06-18 | Initiated | B. Riley FBR, Inc. | Buy |
| May-16-18 | Upgrade | Citigroup | Neutral → Buy |
| May-11-18 | Initiated | BofA/Merrill | Buy |
View All
Alkermes Plc Stock (ALKS) Latest News
Applying Elliott Wave Theory to Alkermes plcDay Trade & Breakout Confirmation Trade Signals - newser.com
How Alkermes plc (8AK) stock valuation compares with sector2025 Sector Review & Low Risk High Win Rate Picks - newser.com
Why Alkermes plc stock is seen as undervaluedQuarterly Portfolio Review & High Conviction Trade Alerts - newser.com
What moving averages say about Alkermes plcQuarterly Portfolio Summary & Daily Oversold Stock Bounce Ideas - newser.com
Risk vs reward if holding onto Alkermes plcGDP Growth & Technical Entry and Exit Alerts - newser.com
Is Alkermes plc (8AK) stock at risk of policy regulationGold Moves & Weekly Chart Analysis and Guides - newser.com
Relative strength of Alkermes plc in sector analysisJuly 2025 Drop Watch & AI Powered Market Entry Strategies - newser.com
How resilient is Alkermes plc stock in market downturnsOptions Play & Expert-Curated Trade Recommendations - newser.com
Is Alkermes plc (8AK) stock a safe buy pre earningsCEO Change & Weekly Watchlist for Hot Stocks - newser.com
What to do if you’re stuck in Alkermes plc2025 Historical Comparison & Weekly Setup with High ROI Potential - newser.com
Why Alkermes plc stock appeals to analysts2025 Breakouts & Breakdowns & Daily Profit Maximizing Trade Tips - newser.com
What recovery options are there for Alkermes plc2025 Price Momentum & Daily Market Momentum Tracking - newser.com
Applying Wyckoff theory to Alkermes plc stockMarket Sentiment Review & Safe Swing Trade Setup Alerts - newser.com
Price momentum metrics for Alkermes plc explained2025 Market Trends & Growth Focused Stock Pick Reports - newser.com
Can Alkermes plc stock maintain growth trajectoryEntry Point & AI Forecasted Entry/Exit Points - newser.com
Is Alkermes plc forming a bottoming baseGap Down & Weekly Setup with High ROI Potential - newser.com
Exit strategy if you’re trapped in Alkermes plcJuly 2025 Closing Moves & Safe Swing Trade Setup Alerts - newser.com
Jennison Associates LLC Buys New Position in Alkermes plc $ALKS - MarketBeat
State of New Jersey Common Pension Fund D Boosts Stock Holdings in Alkermes plc $ALKS - MarketBeat
Alkermes plc (NASDAQ:ALKS) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Alkermes (NASDAQ:ALKS) Rating Increased to Strong-Buy at Wall Street Zen - MarketBeat
Moody Aldrich Partners LLC Has $1.92 Million Stock Position in Alkermes plc $ALKS - MarketBeat
Order flow analysis tools used on Alkermes plcMarket Risk Analysis & Stock Portfolio Risk Management - newser.com
Alkermes plc Just Recorded A 62% EPS Beat: Here's What Analysts Are Forecasting Next - simplywall.st
Can Alkermes plc stock deliver consistent earnings growthMarket Sentiment Report & Free Growth Oriented Trading Recommendations - newser.com
Real time social sentiment graph for Alkermes plcBuy Signal & Free Accurate Trade Setup Notifications - newser.com
Published on: 2025-10-31 00:36:26 - newser.com
RBC Capital Keeps Their Buy Rating on Alkermes (ALKS) - The Globe and Mail
Alkermes Plc Stock (ALKS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.35%
0.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):